OSTIN TECHNOLOGY GROUP CO LT
OSTNASDAQTrading Snapshot
- Day Range
- $1.67 – $1.72
- 52-Week Range
- $1.35 – $235.00
- Volume
- $6.42B
- Avg Volume
- $5.64B
- Shares Outstanding
- 6.0M
- Next Earnings
- Dec 14, 2026
Fundamentals Snapshot
- Annual Revenue
- $40M
- Last Q Revenue
- $18M
- P/E Ratio
- -0.8
- P/S Ratio
- 0.3x
- EPS (TTM)
- $-1.61
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +3972.5%
Why Investors Own OST
- ✓High-growth profile — revenue up -2.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 39% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
OSTIN TECHNOLOGY GROUP CO LT
OST
StockOtter · stockotter.spaceAbout OSTIN TECHNOLOGY GROUP CO LT
Ostin Technology Group Co., Ltd., a company based in China, specializes in the creation and production of sophisticated thin-film transistor liquid crystal display (TFT-LCD) modules, along with essential polarizers. Its extensive product portfolio encompasses comprehensive TFT-LCD solutions, covering critical components such as drive ICs, TCON boards, and power supplies. Additionally, Ostin manufactures advanced backlight systems, specialized display modules, liquid crystal display units, interactive touch panel modules, and intelligent display terminals. The polarizers it produces are integral to these TFT-LCD display units. These versatile display modules find application across a wide array of sectors. In consumer electronics, they are integral to devices like all-in-one PCs, desktop monitors, laptops, and tablets. The automotive industry utilizes Ostin's displays for critical components such as dashboards, navigation systems, and in-car multimedia interfaces. Furthermore, their durable outdoor LCD displays are deployed for dynamic multimedia graphics, including commercial advertisements, promotional content, sports scoreboards, and traffic advisories. Sales channels include direct engagements with end-users as well as distribution through system integrators designated by its clientele. Established in 2010, Ostin Technology Group Co., Ltd. is headquartered in Nanjing, China, and operates its manufacturing facilities within the country.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)
New York, New York and Rockville, Maryland--(Newsfile Corp. - September 24, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immun
OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program
FDA aligns with MHRA and EMA on adaptive design for Phase 3 trial After successful Scientific Advice Meeting, Company accepts MHRA request to become he Company's' sponsor into Project Orbis to harmonize regulatory review
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial
71.2% 3-year overall survival for OST-HER2-treated patients vs. 45.8% comparable combined historical control (p = 0.002) The two remaining patients who have not yet reached the 3-year timepoint from enrollment have trial
OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance
Management will participate at Jefferies Global Healthcare Conference, H.C. Wainwright Global Investment Conference, ROTH Healthcare Opportunities Conference Management and business development advisors will attend BioJa
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma
Meeting to occur in mid-September 2026 Interim 3-year Overall Survival data expected early September, 2026 Decisions on appropriate comparator arm to interpret OST-HER2 clinical efficacy, RMAT designation and Rolling Rev